◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Divi's Laboratories Limited (DIVISLAB) Revenue 2023–2026

Name: Divi's Laboratories Limited (DIVISLAB) revenue history 2023-2026
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-09-20

Divi's Laboratories Limited annual revenue for fiscal 2026 was ₹104.8 billion, an increase of 12.3% from ₹93.2 billion in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

DIVISLAB Annual Revenue

Revenue (annual)	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Total Revenue	₹104.8B	₹93.2B	₹78.0B	₹76.7B

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

DIVISLAB Quarterly Revenue

Revenue (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-06-30	2025-03-31
Total Revenue	₹30.8B	₹28.3B	₹26.0B	₹24.1B	₹25.9B

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Revenue at Comparable Companies

4502 Revenue — Takeda Pharmaceutical Company Limited
SUNPHARMA Revenue — Sun Pharmaceutical Industries Limited
4507 Revenue — Shionogi & Co., Ltd.
TORNTPHARM Revenue — Torrent Pharmaceuticals Limited
4523 Revenue — Eisai Co., Ltd.
4151 Revenue — Kyowa Kirin Co., Ltd.

More DIVISLAB metrics: Gross Profit · Operating Income · Net Income · EPS · Free Cash Flow

All DIVISLAB financial statements → Interactive DIVISLAB charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.